Last reviewed · How we verify
GSK706769 & KALETRA
GSK706769 & KALETRA is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK706769 & KALETRA |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK706769 & KALETRA CI brief — competitive landscape report
- GSK706769 & KALETRA updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK706769 & KALETRA
What is GSK706769 & KALETRA?
GSK706769 & KALETRA is a Small molecule drug developed by GlaxoSmithKline.
Who makes GSK706769 & KALETRA?
GSK706769 & KALETRA is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK706769 & KALETRA in?
GSK706769 & KALETRA is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: GSK706769 & KALETRA vs similar drugs
- Pricing: GSK706769 & KALETRA cost, discount & access